Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006

AIDS Research and Human Retroviruses

Volumn 24, Issue 3, 2008, Pages 355-362

  Vercauteren, Jurgen ^a   Derdelinckx, Inge ^a   Sasse, André ^b   Bogaert, Marleen ^c   Ceunen, Helga ^a   De Roo, Ann ^d   De Wit, Stephane ^e   Deforche, Koen ^a   Echahidi, Fedoua ^f   Fransen, Katrien ^d   Goffard, Jean Christophe ^g   Goubau, Patrick ^h   Goudeseune, Elodie ^e   Yombi, Jean Cyr ^h   Lacor, Patrick ^f   Liesnard, Corinne ^g   Moutschen, Michel ⁱ   Pierard, Denis ^f   Rens, Roeland ^a   Schrooten, Yoeri ^a   Vaira, Dolores ⁱ   Van Den Heuvel, Annelies ^d   Van Der Gucht, Bea ^c   Van Ranst, Marc ^a   Van Wijngaerden, Eric ^a   Vandercam, Bernard ^h   Vekemans, Marc ^d   Verhofstede, Chris ^c   Clumeck, Nathan ^e   Vandamme, Anne Mieke ^a   Van Laethem, Kristel ^a   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^e SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^f UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^g ERASME HOSPITAL   (Belgium)

^h CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

ⁱ UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; ZIDOVUDINE;

ADULT; AGED; ARTICLE; BELGIUM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GENOTYPE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; VIRUS RESISTANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; BELGIUM; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROSPECTIVE STUDIES; QUESTIONNAIRES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

EID: 41449093907     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0212     Document Type: Article

References (30)

1. Geretti AM: Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis 2007;20:22-32.
2. Lama JR, Sanchez J, Suarez L, et al.: Linking HIV and antiretroviral drug resistance surveillance in Peru: A model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr 2006;42:501-505.
3. Shet A, Berry L, Mohri H, et al.: Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: A decade of experience. J Acquir Immune Defic Syndr 2006;41:439-446.
4. Wensing AM and Vercauteren J: Transmission of drug resistant HIV in Europe remains limited to single classes. AIDS 2008, in press.
5. Shafer RW, Rhee SY, Pillay D, et al.: HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007;21:215-223.
6. Vercauteren J and Vandamme AM: Algorithms for the interpretation of HIV-1 genotypic drug resistance information. Antiviral Res 2006;71:335-342.
7. Ghosn J, Pellegrin I, Goujard C, et al.: HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006;20:159-170.
8. Brenner BG, Roger M, Routy JP, et al.: High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007;195:951-959.
9. Van Laethem K, Schrooten Y, Lemey P, et al.: Consecutive transmission of dual-class resistant HIV-1 in untreated patients. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5-8, 2006.
10. Vandamme AM, Sonnerborg A, Ait-Khaled M, et al.: Updated European recommendations for the clinical use of HIV drug resistance testing. Antiviral Ther 2004;9:829-848.
11. Sax PE, Islam R, Walensky RP, et al.: Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005;41:1316-1323.
12. Van Vaerenbergh K, Debaisieux L, De Cabooter N, et al.: Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium. Antiviral Ther 2001;6:63-70.
13. Derdelinckx I, Van Laethem K, Maes B, et al.: Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response. J Acquir Immune Defic Syndr 2004;37:1664-1666.
14. Derdelinckx I, Van Laethem K, De Roo A, et al.: Prospective collection of data on the prevalence of transmitted resistance in newly diagnosed HIV-infected individuals in Belgium in 2003. Second European HIV Drug Resistance Workshop, Rome, 11-13 March 2004.
15. Weinstein MC, Goldie SJ, Losina E, et al.: Use of genotypic resistance testing to guide HIV therapy: Clinical impact and cost-effectiveness. Ann Intern Med 2001;134:440-450.
16. Maes B, Schrooten Y, Snoeck J, et al.: Performance of ViroSeq HIV-1 genotyping system in routine practice at a Belgian clinical laboratory. J Virol Methods 2004;119:45-49.
17. Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF, and Vandamme AM: A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antiviral Ther 2002;7:123-129.
18. de Oliveira T, Deforche K, Cassol S, et al.: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005;21:3797-3800.
19. Palma AC, Araujo F, Duque V, Borges F, Paixao MT, and Camacho R: Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal. Infect Genet Evol 2007;7:391-398.
20. Paraskevis D, Magiorkinis E, Katsoulidou A, et al.: Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece. Virus Res 2005;112:115-122.
21. Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
22. Leigh Brown AJ, Frost SD, Mathews WC, et al.: Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003;187:683-686.
23. Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, and Heneine W: Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci USA 2001;98:13907-13912.
24. Hammer SM, Saag MS, Schechter M, et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-843.
25. Van Laethem K, Van Vaerenbergh K, Schmit JC, et al.: Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J Acquir Immune Defic Syndr 1999;22:107-118.
26. Van Laethem K, Schrooten Y, Lemey P, et al.: Consecutive transmission of dual-class resistant HIV-1 in untreated patients. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5-8, 2006.
27. Masquelier B, Bhaskaran K, Pillay D, et al.: Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: Data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr 2005;40:505-511.
28. UK Collaborative Group on HIV Drug Resistance: Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 2007;21:1035-1039.
29. Saul J, Erwin J, Sabin CA, Kulasegaram R, and Peters BS: The relationships between ethnicity, sex, risk group, and virus load in human immunodeficiency virus type 1 antiretroviral-naive patients. J Infect Dis 2001;183:1518-1521.
30. Smith PR, Sarner L, Murphy M, et al.: Ethnicity and discordance in plasma HIV-1 RNA viral load and CD4+ lymphocyte count in a cohort of HIV-1-infected individuals. J Clin Virol 2003;26:101-107.